PRX 202
Alternative Names: PRX-202Latest Information Update: 08 Dec 2022
At a glance
- Originator PRAZER THERAPEUTICS
- Class Antivirals; Small molecules
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis B
Most Recent Events
- 25 Nov 2022 Early research in Hepatitis B in South Korea (unspecified route) as of November 2022 (Prazer Therapeutics pipeline, November 2022)